Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Adrenergic Agonists: Mixed-Action Agents01:28

Adrenergic Agonists: Mixed-Action Agents

Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psychedelics and Entactogens.

Journal of medicinal chemistry·2026
Same author

Neuroglial P2Y<sub>1</sub> receptor signalling differentially contributes to inflammatory neurodegeneration.

Journal of neuroinflammation·2026
Same author

Development of Novel Lysosome-Targeting Chimera by Non-covalent-Type Fc-IGF2 Complex (Fc-LYTAC) for Target Membrane Protein Degradation.

Chemical & pharmaceutical bulletin·2026
Same author

Inhibitors of Ectonucleotidase CD39 for Immunotherapy of Cancer and Infections─Recent Developments and Future Perspectives.

Journal of medicinal chemistry·2026
Same author

Nucleotide-Derived Competitive Inhibitors of Ectonucleotidase CD39─A Promising Extracellular Target for Immunotherapy of Cancer.

Journal of medicinal chemistry·2026
Same author

Mechanism of GPR84 allosteric modulation at a helix 8-proximate site.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Jun 8, 2026

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

Xanthines as adenosine receptor antagonists.

Christa E Müller1, Kenneth A Jacobson

  • 1University of Bonn, Pharmaceutical Institute, An der Immenburg 4, 53121, Bonn, Germany. christa.mueller@uni-bonn.de

Handbook of Experimental Pharmacology
|September 23, 2010
PubMed
Summary

Caffeine and theophylline were the first adenosine receptor (AR) antagonists. Researchers have since developed potent, selective AR antagonists for all four subtypes.

Area of Science:

  • Pharmacology
  • Medicinal Chemistry

Background:

  • Adenosine receptors (ARs) are crucial drug targets.
  • Caffeine and theophylline are known non-selective AR antagonists with micromolar affinity.
  • Developing selective AR antagonists is a key research area.

Purpose of the Study:

  • To review the development of adenosine receptor antagonists.
  • To highlight the synthesis and evaluation of AR antagonist derivatives and analogues.

Main Methods:

  • Literature review of AR antagonist research.
  • Synthesis and in vitro evaluation of novel AR antagonist compounds.

Main Results:

  • Initial non-selective AR antagonists (caffeine, theophylline) have micromolar affinities.

More Related Videos

Determining the Serum Stability of Human Adenosine Deaminase 1 Enzyme
04:17

Determining the Serum Stability of Human Adenosine Deaminase 1 Enzyme

Published on: September 27, 2024

Related Experiment Videos

Last Updated: Jun 8, 2026

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

Determining the Serum Stability of Human Adenosine Deaminase 1 Enzyme
04:17

Determining the Serum Stability of Human Adenosine Deaminase 1 Enzyme

Published on: September 27, 2024

  • Numerous AR antagonist derivatives and analogues have been synthesized.
  • Highly potent and subtype-selective AR antagonists have been successfully developed.

    • Conclusions:

    • Significant progress has been made in developing selective adenosine receptor antagonists.
    • These selective antagonists offer potential for targeted therapeutic applications.